Practically Speaking: EVP the MVP for Untreated Advanced Urothelial Cancer

To be added to the distribution list, please email: DDeCastro@southlake.ca

In this episode of MedOncNow, Dr. Christian Kollmannsberger discusses 1st line Enfortumab Vedotin + Pembrolizumab (EVP) in the treatment of advanced urothelial carcinoma. This is timely given we now have access to both Enfortumab and Pembrolizumab through company sponsored access programs. 

Key Opinion Leader: 

Christian Kollmannsberger MD FRCPC
Clinical Professor of Medicine
Head, Department of Medical Oncology
BC Cancer - Vancouver Cancer Centre
Div. of Medical Oncology
University of British Columbia

Host:
Shaqil Kassam MD. MSc. FRCPC
skassam@southlake.ca
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Previous episodes: https://www.blogtalkradio.com/medoncnow

X- @medoncnow